NASDAQ: QNTMQuantum Biopharma Ltd Stock
$3.83-0.17 (-4.25%)
Updated Jun 12, 2026
QNTM Price
$3.83
Fair Value Price
$0.01
Market Cap
$14.89M
52 Week Low
$2.07
52 Week High
$38.25
P/E
-0.63x
P/B
34.02x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$22.58M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
27.46
Operating Cash Flow
-$7M
Beta
1.07
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
QNTM Overview
Quantum BioPharma Ltd., a biopharmaceutical firm headquartered in Toronto, Canada, is dedicated to the discovery and advancement of biotechnological solutions and drug candidates. The company focuses on addressing complex neurodegenerative, inflammatory, and metabolic conditions, alongside alcohol use disorder, with its pipeline featuring a range of drug candidates at varying stages of development. Its operations are divided into two main divisions: its core biopharmaceutical activities and strategic investment holdings. A flagship asset is Lucid-MS, a novel, proprietary chemical entity currently in Phase 2 clinical trials. Preclinical data indicates its potential to prevent and reverse the degradation of myelin, a key process underlying multiple sclerosis. Furthermore, Quantum BioPharma is developing a therapeutic solution for alcohol addiction, intended for application in hospital and clinical environments. The company's strategic investments portfolio includes various loans collateralized by residential real estate. Previously known as FSD Pharma Inc., the company adopted its current name, Quantum BioPharma Ltd., in August 2024.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine QNTM's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Pharmaceutical
Industry Rating
B
QNTM
Ranked#43 of 51
Ranked#43 of 51
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $38.48 | A | |
| $34.64 | A | |
| $16.48 | A |
Be the first to know about important QNTM news, forecast changes, insider trades & much more!
QNTM News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how QNTM scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
QNTM ($3.83) is overvalued by 43,157.5% relative to our estimate of its Fair Value price of $0.01 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
QNTM ($3.83) is not significantly undervalued (43,157.5%) relative to our estimate of its Fair Value price of $0.01 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
QNTM is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more QNTM due diligence checks available for Premium users.
Valuation
QNTM fair value
Fair Value of QNTM stock based on Discounted Cash Flow (DCF)
Price
$3.83
Fair Value
$0.01
Overvalued by
43,157.50%
QNTM ($3.83) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
QNTM ($3.83) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
QNTM is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
QNTM price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.63x
Industry
-5.05x
Market
14.15x
QNTM price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
34.02x
Industry
1.57x
QNTM is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
QNTM's financial health
Profit margin
Revenue
$0.0
Net Income
-$9.8M
Profit Margin
0%
QNTM's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$10.8M
Liabilities
$11.8M
Debt to equity
27.46
QNTM's short-term liabilities ($12.02M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
QNTM's short-term assets ($7.62M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
QNTM's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
QNTM's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.2M
Investing
-$2.1M
Financing
$5.1M
QNTM's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
QNTM vs Pharmaceutical Stocks
Quantum Biopharma Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.